Results 131 to 140 of about 816 (186)
Some of the next articles are maybe not open access.
[Hirudin and hirudin fragments].
Annales de cardiologie et d'angeiologie, 1993Hirudin is a potent and specific thrombin inhibitor: compared with heparin thrombin inhibition occurs directly and does not require the presence of plasma cofactors. Recombinant hirudin is well tolerated in animals and in healthy volunteers. Its clearance half-life after IV administration range from 1 to 2 hours and its bioavailability after ...
A, Deschamps, M, Samama
openaire +1 more source
Hirudin and hirudin analogues as new anticoagulant agents
Current Opinion in Hematology, 1995Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation. As opposed to unfractionated heparin, hirudin and hirulog effectively suppress clot-bound thrombin, making
G F, Pineo, R D, Hull
openaire +2 more sources
Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin
Pathophysiology of Haemostasis and Thrombosis, 1991In addition to its classical active-site regions (catalytic site and adjacent regions), α-thrombin has a unique anion-binding exosite, which is functionally independent of the catalytic site and is involved in fibrin(ogen) recognition. This exosite also accounts for adhesion to negatively charged surfaces (e.g., glass), binding to cell surfaces, and ...
J W, Fenton +3 more
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1993
Abstract:A brief outline is presented of a proposed trial of Hirulog versus heparin after thrombolytic therapy with streptokinase (SK). The lower patency rates achieved with SK compared with tissue plasminogen activator (t‐PA) suggest that a potent thrombin specific agent may be more important for SK than for t‐PA therapy.
openaire +2 more sources
Abstract:A brief outline is presented of a proposed trial of Hirulog versus heparin after thrombolytic therapy with streptokinase (SK). The lower patency rates achieved with SK compared with tissue plasminogen activator (t‐PA) suggest that a potent thrombin specific agent may be more important for SK than for t‐PA therapy.
openaire +2 more sources
Seminars in Thrombosis and Hemostasis, 1997
Recombinant (r-) hirudins and PEG-hirudin are currently tested for anticoagulant therapy. For their concentration measurement, radioimmunoassay and HPLC methods are available. The separation of r- and PEG-hirudin is currently performed by HPLC. However, the sensitivity of the method is low. Capillary electrophoresis is a rapid, selective technique that
R, Malsch, A, Timmermann, J, Harenberg
openaire +2 more sources
Recombinant (r-) hirudins and PEG-hirudin are currently tested for anticoagulant therapy. For their concentration measurement, radioimmunoassay and HPLC methods are available. The separation of r- and PEG-hirudin is currently performed by HPLC. However, the sensitivity of the method is low. Capillary electrophoresis is a rapid, selective technique that
R, Malsch, A, Timmermann, J, Harenberg
openaire +2 more sources
Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin
Thrombosis and Haemostasis, 2003SummaryRecombinant hirudin (r-hirudin) is a potent direct thrombin inhibitor with immunogenic properties. Anti-hirudin antibodies (aHAb) are detected in up to 74% of patients treated with r-hirudin for more than 5 days. aHAb may alter the pharmaco-kinetics and pharmacodynamics of r-hirudin.The effects of aHAb on the pharmacokinetics of r-hirudin were ...
Hudek, Renata +6 more
openaire +3 more sources
Use of fragments of hirudin to investigate thrombin‐hirudin interaction
European Journal of Biochemistry, 1990Site‐directed mutagenesis was used to create hirudin in which Asn52 was replaced by methionine. Cyanogen bromide cleavage at this unique methionine resulted in two fragments. These fragments have been used to study the kinetic mechanism of the inhibition of thrombin by hirudin and to identify areas of the two molecules which interact with each other ...
S, Dennis +3 more
openaire +2 more sources
Blood, 2011
Abstract Abstract 4321 Recombinant versions of hirudin such as lepirudin (Refludan®) and desirudin (Iprivask®) are currently used as parenteral anticoagulants for various indications. The recombinant hirudin preparations differ from the natural hirudin in lacking a sulfate group on tyrosine at the 63rd position and a ...
Vijaya L Paramatmuni +5 more
openaire +1 more source
Abstract Abstract 4321 Recombinant versions of hirudin such as lepirudin (Refludan®) and desirudin (Iprivask®) are currently used as parenteral anticoagulants for various indications. The recombinant hirudin preparations differ from the natural hirudin in lacking a sulfate group on tyrosine at the 63rd position and a ...
Vijaya L Paramatmuni +5 more
openaire +1 more source
Pharmacology of Recombinant Hirudin
Seminars in Thrombosis and Hemostasis, 2002Hirudin is the anticoagulative product of the salivary glands of the medical leech Hirudo medicinalis. It is characterized by a direct, bifunctional inhibition mechanism and a high, exclusive specificity and a strong ability to bind to thrombin (tight binding).
openaire +2 more sources
Hirudin for Diagnostic Purposes
Pathophysiology of Haemostasis and Thrombosis, 1991Hirudin serves as a versatile tool for the control of thrombin activity in hemostaseology. It may be added in excess to blood, plasma or test mixtures to prevent catalytic and nonenzymatic effects of thrombin. It may be used to quench thrombin activity upon extensive or limited action.
openaire +2 more sources